JP Morgan Chase
MJN

JP Morgan Chase’s Mead Johnson Nutrition Company MJN Stock Holding History

JP Morgan Chase’s Portfolio MJN Stock Details MJN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-174,500
Closed -$15.8M – 5026
2016
Q2 		$15.8M Buy
+174,500
New +$14.8M ﹤0.01% 1545

Other funds holding MJN

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
FNBOO
First National Bank of Omaha Omaha, Nebraska $3.24B AUM 18.68% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return
WEC
Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return

JP Morgan Chase's MJN Position: Q2 2017 in Review

JP Morgan Chase sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 2,016,923 shares — an estimated $180M sold.

JP Morgan Chase first reported a position in MJN in Q2 2013 and held it in 16 quarters. The position peaked at $180M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • JP Morgan Chase reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • JP Morgan Chase sold 2,016,923 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $180M.
  • JP Morgan Chase first reported a position in Mead Johnson Nutrition Company in Q2 2013 and held it in 16 quarters.
  • JP Morgan Chase's Mead Johnson Nutrition Company position peaked at $180M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on JP Morgan Chase's 13F filing for Q2 2017, filed 9 Aug 2017.